Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, School of Immunology and Microbial Sciences, King's College London, London, SE1 9RT, UK.
School of Immunology and Microbial Sciences, King's College, London, UK.
Adv Ther. 2022 Jun;39(6):2323-2341. doi: 10.1007/s12325-022-02110-8. Epub 2022 Apr 30.
Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.
嗜酸粒细胞相关疾病(EADs)是一系列异质性疾病,其中嗜酸粒细胞被认为在病理上发挥关键作用。EADs 包括常见疾病,如嗜酸粒细胞性哮喘和慢性鼻-鼻窦炎,以及罕见疾病,如嗜酸性粒细胞增多综合征(HES)和嗜酸粒细胞性胃肠病(EGIDs)。EADs 给患者带来了巨大的负担,包括慢性、衰弱性症状、增加的经济负担、降低的健康相关生活质量,以及需要多次就诊于多个不同的医疗保健专业人员(HCPs)、急诊部门和/或医院。HCPs 对 EAD 的识别不足常常导致诊断延迟,这进一步延迟了患者获得适当治疗的机会,导致健康结果不佳。本宪章的目的是概述患者在管理其病情方面的关键权利和期望,并制定一项雄心勃勃的行动计划,以改善 EAD 患者的健康结果:(1)EAD 患者、其照顾者、HCPs 和公众必须对 EAD 有更多的认识和教育;(2)EAD 患者必须及时、准确地诊断;(3)所有 EAD 患者都必须在必要时获得适当的多学科团队;以及(4)EAD 患者必须能够获得安全有效的治疗方案,而不会因不必要的监管延迟而受到影响。本宪章中描述的原则展示了 EAD 患者必须获得的优质护理的核心要素,它们代表了减少患者和护理者负担并改善患者结局的明确步骤。我们敦促全球的 HCPs、医疗保健系统和政策制定者迅速采纳这些原则,以确保 EAD 患者能够及时获得准确的诊断,并在适当的环境中获得高水平的护理和治疗。